

Shao-Chun Wang, Ph.D.

Address: C1-6F, No. 350, Jingmao 1st Rd., Beitun Dist., Taichung City
Taiwan, 406040

TEL:04-22053366/7923 (Office)/7914 (Lab)

E-mail: wangsc@mail.cmuh.org.tw ; scpwang@mail.cmu.edu.tw ;

Web: <https://scwlab.wordpress.com>

**Education**

- 1984-1988 B.Sc. - Pharmacy, Taipei College of Medicine, Taipei, Taiwan
1990-1995 Ph.D. - Genetics and Cell Biology, University of Minnesota Twin Cities,
Minnesota, USA

Research and Professional Positions Held in Chronological Sequence

- 1996-2000 Post-doctoral fellow of tumor biology, University of Texas M. D. Anderson
Cancer Center, Houston, Texas USA
- 2000-2002 Instructor, University of Texas M. D. Anderson Cancer Center, Department of
Molecular and Cellular Oncology, Houston, Texas USA
- 2002-2007 Research-track Assistant Professor, University of Texas M. D. Anderson Cancer
Center, Department of Molecular and Cellular Oncology, Houston, Texas USA
- 2007-2014 Tenure-track Assistant Professor, Department of Cancer Biology, University of
Cincinnati College of Medicine, Cincinnati, Ohio USA
- 2014-2016 Associate Professor, Department of Cancer Biology, University of Cincinnati
College of Medicine, Cincinnati, Ohio USA
- 2013-present -Member, Cincinnati Cancer Center (CCC)
-Member, University of Cincinnati Cancer Institute (UCCI)
- 2016-present -Professor, Graduate Institute of Biomedical Sciences, China Medical University,
Taichung City, Taiwan
-Investigator, Center of Molecular Medicine, China Medical University Hospital,
Taichung City, Taiwan
- Adjunct Associate Professor, Department of Cancer Biology, University of
Cincinnati College of Medicine, Cincinnati, Ohio USA
- Adjunct Professor, Department of Biotechnology, Asia University, Taiwan
- 2016-2020 Program Director, China Medical University-Academia Sinica PhD Graduate
Program of Translational Medicine, China Medical University, Taiwan
- 2016-2024 Program Director, China Medical University-Academia Sinica PhD Graduate
Program of Cancer Biology and Drug Development, China Medical University,
Taiwan
- 2016-2025 Deputy Director, Center for Molecular Medicine, China Medical University
Hospital, Taichung City, Taiwan
- 2019-2023 Associate Dean, College of Medicine, China Medical University, Taichung City,
Taiwan
- 2019-2025 Director, Research Center for Cancer Biology
- 2025-present Chair, China Medical University Hospital IACUC

Awards and Honors (past 5 years)

2021	Scholar of Global Networking Talent Plan, Ministry of Education, Taiwan
2021	Elsevier global top 2% science-wide author (current)
2022	Elsevier global top 2% science-wide author (current and career)
2022	19 th National Innovation Award (top 15 out of ~500 competing teams)
2023	National Health Research Institute (NHRI) Research Award
2024	Elsevier global top 2% science-wide author (current and career)
2024	21 st National Innovation Advance Award
2025	National Science and Technology Council (NSTC) Future Tech Award
2025	Elsevier global top 2% science-wide author (current and career)
2025	22 nd National Innovation Advance Award

Research Interests

My laboratory uses integrated cellular, molecular, genetic, and translational approaches to investigate mechanisms underlying human diseases. We combine mechanistic studies in cell-based systems with genetically engineered mouse models, patient-derived organoids, and clinically annotated human specimens. Through close clinical and international collaborations, this strategy enables us to define disease mechanisms, establish biologic relevance across complementary model systems, and advance discoveries toward biomarker development and therapeutic translation.

Major current research interests focus on the following areas:

1. Tumor immune microenvironment and cancer progression - We study how tumor, stromal, and immune cells interact to shape immune suppression, immune cell exhaustion, inflammatory responses, metastasis, and treatment outcome, with the goal of unveiling the underlining mechanisms and translate the knowledge to targeted therapy to improve anti-tumor immunity.
2. Tumor-selective therapeutic targeting and biomarker-guided drug development - We develop biomarkers and targeted therapies that exploit tumor-specific molecular features to improve treatment selectivity, efficacy, and safety. Our work includes antibody–drug conjugates (ADCs), antibody-based platforms, and small-molecule strategies designed to enhance therapeutic targeting, reduce off-target toxicity and overcome tumor-associated immune suppression.
3. Ovarian endocrine regulation and obesity - We investigate how ovarian steroid hormone production is regulated within specific cellular compartments of the ovary and how these endocrine programs influence systemic energy metabolism. Our work focuses on the molecular mechanisms governing estrogen biosynthesis in granulosa cells and their relevance to obesity and obesity-associated metabolic disorders.